IJCRR - 8(2), January, 2016
Pages: 23-28
ASSESSMENT OF BIOCHEMICAL RISK FACTORS OF CARDIO METABOLIC SYNDROME IN PATIENTS OF HYPOTHYROIDISM
Author: Meghana K. Padwal, Bapu Kamble, Pinky Sawlani, Rajani R. Melinkeri
Category: Healthcare
[Download PDF]
Abstract:
Introduction: Hypothyroidism is the second most prevalent endocrinal disorder in India. Most of existing data supports that thyroid disease is associated with increased cardiovascular risk which is mainly attributed to hemodynamic alteration as well as to a high risk of atherosclerosis, dylipidemia and insulin resistance. Aim: To investigate relationship between thyroid function and biochemical risk factors of cardiovascular diseases. Material and Methods: The present study was a cross-sectional, prospective. The study population was comprised of a total of ninety (90) participants (30 new cases of overt hypothyroidism, 30 new cases of subclinical hypothyroidism and 30 age and gender matched controls). Estimation of serum Thyroid profile and Insulin (fT3 , fT4 and TSH) was done by CLIA while Glucose and Lipid profile were estimated by biochemistry autoanalyzer. Insulin Resistance was calculated by HOMA IR score. Statistical Analysis: Data obtained was statistically analyzed by using student “t” test. Results: We found statistically significant rise in the levels of serum cholesterol triglycerides VLDL and LDL in the cases of overt hypothyroidism than controls. HDL levels are low in overt hypothyroidism. We also found statistically significant rise in the levels of blood glucose, serum insulin and HOMA IR score in cases of overt hypothyroidism than controls. Conclusion: Overt Hypothyroidism is at the risk of developing cardiovascular diseases and type II DM.
Keywords: Hypothyroidism, Cardiovascular diseases, Type II DM
Citation:
Meghana K. Padwal, Bapu Kamble, Pinky Sawlani, Rajani R. Melinkeri. ASSESSMENT OF BIOCHEMICAL RISK FACTORS OF CARDIO METABOLIC SYNDROME IN PATIENTS OF HYPOTHYROIDISM International Journal of Current Research and Review. 8(2), January, 23-28
References:
1. Harper’s Biochemistry (1998): Published by a Lange Medical Book. Thyroid Hormones. Ed. 25th : 561.
2. K Boelaert and J A Franklyn. Thyroid hormone in health and disease. Journal of Endocrinology. 2005;187: 1–15.
3. HARRISON'S PRINCIPLES OF Internal Medicine (1958): Published by McGraw-Hill Companies. 15th Ed. Disorders of Thyroid Gland. Vol. (2):2063.
4. John W Baynes and Marek H Dominiczak (1999): Published by ELSEVIER MOSBY Medical Biochemistry. The hypothalamicpituitary-adrenal axis. Ed.3rd : 535.
5. Nishiki k et al. Evaluation of oxidative phosphorylation in hearts from enthyroid, hypothyroid, and hyperthyroid rats. Am J Physiol. 1978; (235) ;212-219.
6. Pereira B, Rosa LF, Safi DA et al. Control of Superoxide dismutase, Catalase and glutathione peroxidase activities in rat lymphoid organs by thyroid hormones. J Endocrinol. 1994;(140) :73-77.
7. Desai PM. Disorders of the Thyroid Gland in India. Indian J Pediatr. 1997; (64) : 11-20.
8. Krysiak R, Okopien B, Herman ZS. Subclinical thyroid disorders. Pol MerkurLekarski. 2006; (21): 573-8.
9. Williams Textbook of Endocrinology (2008): Published by Saunders Elseiver, Hypothyroidism ; Ed. 11th : 377.
10. Kostoglou-Athanassiou I, Ntalles K. Hypothyroidism – new aspects of an old disease. HIPPOKRATIA. 2010; (14,2) : 82-87.
11. Cooper DS. Subclinical hypothyroidism. N Engl J Med. 2001; (345) :260-265.
12. Huber G, Staub J-J, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: Prognostic value of thyrotropin, thyroid reserve and thyroid antibodies. J ClinEndocrinolMetab. 2002; (87): 3221-3226.
13. Hollowel JG, Stehling NW, Flanders D, et al. Serum TSH, T4 and thyroid antibodies in the United states population (1998- 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; (887) : 489-499.
14. Klein and K. Ojamaa. Thyroid hormone and the cardiovascular system. The New England Journal of Medicine. (vol. 344, no. 7): 501-509.
15. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi. “Effects of thyroid hormone on the cardiovascular system,” Recent progress in hormone research.(vol. 59) : 31-50.
16. Bakker SJL, Ter Maaten JC, Popp-Snijders C, Slaets JPJ, Heine RJ, Gans ROB. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001; 86: 1206-11.
17. A.K. Campbell. Detection and Quantification of chemiluminescence, in Chemiluminescence principles and applications in Biology and medicine.EllisHorwood.1988; 68-126.
18. Nader Rifai and G. Russell Warnick. Lipids, Lipoproteins, apolipoproteins and other cardiovascular risk factors. Teitz Textbook of Clinical Chemistry. 4th Edition. Section IV. Chapter 26: 943- 48.
19. Stein, E. A. and Mayers, G. L. Lipids, Lipoproteines and Apolipoproteines in Tietz Textbook of clinical Chemistry. Burtis C. A. and Ashwood E. R. (Ed). WB Saunders Company, Second Edition. 1994; (23) : 1002-93.
20. Dominiczak M, McNamara J. The system of cardiovascular prevention. 103-125; Nauk M, Warnick G. Measurement of HighDensity-Lipoproteine Cholesterol. In: Handbook of Lipoprotein Testing (eds. Rifai, Warnick and Dominiczak), 2nd edition.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; (18) : 499–502.
22. Trinder, P. Ann. Clin. Biochem. 1969; (6):24.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fastingplasma glucose and insulin concentrations in man. Diabetologia.1985; (28) : 412-9.
24. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty year follow-up of the Whickham survey. Clin Endocrinol (oxf). 1995; 43: 55-68.
25. Surks M.I., Ortiz, E., Daniels, G.H., Sawin, C.T., Col, N.F., Cobin, R.H.: Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. J. A. M. A. 2004; 291(2):228-238.
26. Tognini S, Polini A, Pasqualetti G, Ursino S, Caraccio N, Ferdeghini M, Monzani F.Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. Thyroid. 2012 Nov;22(11):1096-103.
27. Xu C, Yang X, Liu W, Yuan H, Yu C, Gao L, Zhao J. Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a cross-sectional design. NutrMetab (Lond). 2012 May 23;9(1):44.
28. Benetti-Pinto CL, Berini Piccolo VR, Garmes HM, TeatinJuliato CR.Subclinical hypothyroidism in young women with polycystic ovary syndrome: an analysis of clinical, hormonal, and metabolic parameters. Fertil Steril. 2013 Feb;99(2):588-92.
29. Garduño-Garcia Jde J, Alvirde-Garcia U, López-Carrasco G, Padilla Mendoza ME, Mehta R, Arellano-Campos O, Choza R, Sauque L, Garay-Sevilla ME, Malacara JM, Gomez-Perez FJ, Aguilar-Salinas CA. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol. 2010 Aug;163(2):273-8.
30. Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J. 2007 Feb;54(1):71-6.
31. Shantha GP, Kumar AA, Jeyachandran V et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross- sectional study from South India. Thyroid Res. 2009 Mar 9;2(1):2.
32. Purohit P, Mathur R Hypertension association with serum lipoproteins, insulin, insulin resistance and C-Peptide: unexplored forte of cardiovascular risk in hypothyroidism. N Am J Med Sci. 2013 Mar;5(3):195-201.
33. Khan SH, Khan FA, Ijaz A, Sattar A, Dilawar M, Hashim R. Spectrum of lipid and lipoprotein indices in human subjects with insulin resistance syndrome. J Ayub Med Coll Abbottabad. 2008 Jul-Sep;20(3):17-22.
34. Chen G, Wu J, Lin Y, Huang B, Yao J, Jiang Q, Wen J, Lin L. Associations between cardiovascular risk, insulin resistance, betacell function and thyroid dysfunction: a cross-sectional study in She ethnic minority group of Fujian Province in China. Eur J Endocrinol. 2010: Nov;163(5):775-82.
35. 26. Lam KS, Chan MK, Yeung RT. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction—effects of treatment. 1986. Q J Med. 59:513–521.
36. Kuusi T, Taskinen MR, Nikkilä EA. Lipoproteins, lipolytic enzymes and hormonal status in hypothyroid women at different levels of substitution. J Clin Endocrinol Metab. 1988. 66:51–56.
37. Bakker SJ, terMaaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206-1211.
38. Kim SR, Tull ES, Talbott EO, Vogt MT and Kuller LH. A hypothesis of synergism: the interrelationship of T3 and insulin to disturbances in metabolic homeostasis. Medical Hypotheses. 2002: 59; 660–666.
39. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-1184.
40. Miura S, Iitaka M, Suzuki S, Fukasawa N, Kitahama S, Kawakami Y, Sakatsume Y, Yamanaka K, Kawasaki S, Kinoshita S, Katayama S, Shibosawa T, Ishii J. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J. 1996 Dec;43(6):657-63.
41. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinos N and Raptis SA. Insulin action in adipose tissue and muscle in hypothyroidism. Journal of Clinical Endocrinology and Metabolism. 2006. 91; 4930–4937.
|